| Toggle Summary
|
Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients
|
|
| Toggle Summary
|
Intersect ENT Quadruples Operation Size with Expansion to New Facility in Menlo Park, Calif.
|
|
| Toggle Summary
|
Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant, Showing Significantly Improved Outcomes For Sinus Surgery
|
|
| Toggle Summary
|
Intersect ENT Announces U.S. Food and Drug Administration Approval for First Drug Releasing Implant for Chronic Sinusitis Patients
|
|
| Toggle Summary
|
Intersect ENT Closes Series C Financing, Recognized for Clinical Science
|
|
| Toggle Summary
|
Sinexus changes name to Intersect ENT, Initiates Pivotal Study
|
|
| Toggle Summary
|
Sinexus Welcomes New CEO and Completes Series B
|
|
